Effectiveness of Chemo-Immunotherapy (CIT) and Novel Therapies in Second or Later Line of Therapy (2L+) for Patients with Relapsed/Refractory (R/R) Aggressive Large B-Cell Lymphoma (LBCL)

被引：1

作者：

Nastoupil, Loretta J. ^{[1
]}

Andersen, Clark R. ^{[1
]}

Ayers, Amy ^{[1
]}

Wang, Yucai ^{[2
]}

Habermann, Thomas M. ^{[2
]}

Chihara, Dai ^{[1
]}

Kahl, Brad S. ^{[3
]}

Link, Brian K. ^{[4
]}

Cohen, Jonathon B. ^{[5
]}

Martin, Peter ^{[6
]}

Lossos, Izidore S. ^{[7
]}

Casulo, Carla ^{[8
]}

Lin, Ruitao ^{[1
]}

Li, Ziyi ^{[1
]}

Larson, Melissa C. ^{[2
]}

Maurer, Matthew J. ^{[2
]}

Huynh, Lynn ^{[9
]}

Gao, Chi ^{[9
]}

Ramasubramanian, Ramya ^{[9
]}

Sheng, Mei ^{[9
]}

Mutebi, Alex ^{[10
]}

Wang, Tongsheng ^{[10
]}

Jun, Monika ^{[10
]}

Wang, Anthony ^{[11
]}

Kamalakar, Rajesh ^{[11
]}

Kalsekar, Anupama ^{[10
]}

Cerhan, James R. ^{[2
]}

Flowers, Christopher R. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[2] Mayo Clin, Rochester, MN USA

[3] Washington Univ, Sch Med St Louis, St Louis, MO USA

[4] Univ Iowa, Carver Coll Med, Iowa City, IA USA

[5] Emory Univ, Atlanta, GA USA

[6] Weill Cornell Med Coll, New York, NY USA

[7] Univ Miami Hlth Syst, Miami, FL USA

[8] Univ Rochester, Med Ctr, Rochester, NY USA

[9] Anal Grp Inc, Boston, MA USA

[10] Genmab, Princeton, NJ USA

[11] AbbVie Inc, Chicago, IL USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-174497

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[11] Clinical Outcomes with Prophylactic Corticosteroid Use for Axicabtagene Ciloleucel (axicel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/ R LBCL): A Multicenter Analysis
Vuyyala, Sowjanya
Corraes, Andre De Menezes Silva
Bailey, Megumi
Iqbal, Madiha
Munoz, Javier L.
Hunter, Bradley
Bansal, Radhika
Patel, Krish
Kharfan-Dabaja, Mohamed A.
Rosenthal, Allison C.
Wang, Yucai
Paludo, Jonas
Johnston, Patrick B.
Bennani, N. Nora
Villasboas, J. C. C.
Durani, Urshila
Ansell, Stephen M.
Lin, Yi
Khurana, Arushi
BLOOD, 2023, 142
[12] Prognostic Impact of Comorbidities on Outcomes of Patients (pts) with Relapsed or Refractory Large B-Cell Lymphoma (r/r LBCL) Treated with Chimeric Antigen Receptor T-Cell Therapy (CART)
Greenbaum, Uri
Hashmi, Hamza
Elsawy, Mahmoud
Kim, Soyoung
Moskop, Amy
Awan, Farrukh T.
Farooq, Umar
Ganguly, Siddhartha
Hematti, Peiman
Jain, Michael D.
Kebriaei, Partow
Locke, Frederick L.
Mead, Elena
Nishihori, Taiga
Olson, Amanda L.
Pennisi, Martina
Perales, Miguel-Angel
Geethakumari, Praveen Ramakrishnan
Shouval, Roni
Shpall, Elizabeth J.
Magalhaes-Silverman, Margarida Magalhaes
Strouse, Christopher
Turtle, Cameron J.
Vallurupalli, Anusha
Wudhikam, Kitsada
Pasquini, Marcelo C.
Ahmed, Sairah
Sorror, Mohamed
BLOOD, 2022, 140 : 4636 - 4638
[13] Modified R-DAOx as salvage therapy in patients with relapsed or refractory diffuse large B-cell lymphoma
Rigacci, L.
Fabbri, A.
Mappa, S.
Nassi, L.
Lenoci, M.
Puccini, B.
Alterini, R.
Chitarrelli, I
Carrai, V
Lauria, F.
Bosi, A.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 61 - 61
[14] Modified R-DHAOx as salvage therapy in patients with relapsed or refractory diffuse large B-cell lymphoma
Fabbri, A.
Rigacci, L.
Lenoci, M.
Mappa, S.
Puccini, B.
Nassi, L.
Chitarrelli, I.
Gozzetti, A.
Alterini, R.
Carrai, V.
Bosi, A.
Lauria, F.
ANNALS OF ONCOLOGY, 2008, 19 : 219 - 220
[15] Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Dyer, Martin J. S.
De Vos, Sven
Ruan, Jia
Flowers, Christopher
Maddocks, Kami J.
Rule, Simon
Hamdy, Ahmed M.
Izumi, Raquel
Slatter, J. Greg
Cheung, Jean
Frigualt, Melanie M.
Wei, Helen
Mourya, Sanchita
Hunder, Naomi N. H.
Fowler, Nathan Hale
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[16] COST-EFFECTIVENESS OF AXICABTAGENE CILOLEUCEL (AXI-CEL) AND TISAGENLECLEUCEL (TISA-CEL) IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL) IN CANADA
Ball, G.
Kuruvilla, J.
Boodoo, C.
Jain, M. D.
VALUE IN HEALTH, 2021, 24 : S39 - S39
[17] A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Kalakonda, Nagesh
Cavallo, Federica
Follows, George
Goy, Andre
Vermaat, Joost S. P.
Casasnovas, Olivier
Lavee, Orly
Maerevoet, Marie
Zijlstra, Josee
Bakhshi, Sameer
Bouabdallah, Reda
Choquet, Sylvain
Gurion, Ronit
Hill, Brian
Jaeger, Ulrich
Sancho, Juan-Manuel
Schuster, Michael
Thieblemont, Catherine
De la Cruz, Fatima
Egyed, Miklos
Mishra, Sourav
Offner, Fritz
Vassilakopoulos, Theodoros
Warzocha, Krzysztof
McCarthy, Daniel
Ma, Xiwen
Corona, Kelly
Saint-Martin, Jean-Richard
Joshi, Anita
Shah, Jatin
Van den Neste, Eric
Canales, Miguel
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S248 - S249
[18] Budget Impact Model of Axicabtagene Ciloleucel (Axi-cel) in a US Population of Patients with Relapsed or Refractory Large B-Cell Lymphoma (R/R-LBCL)
Hathway, Joanne
Purdum, Anna
Lin, Vincent W.
Cyr, Philip
Westin, Jason
Jensen, Ivar
BONE MARROW TRANSPLANTATION, 2018, 53 : 878 - 879
[19] Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL)
Topp, Max S.
van Meerten, Tom
Houot, Roch
Minnema, Monique
Milpied, Noel
Lugtenburg, Pieternella J.
Thieblemont, Catherine
Wermke, Martin
Song, Kevin
Avivi, Irit
Kuruvilla, John
Duehrsen, Ulrich
Chu, Rachel
Zheng, Lianqing
Plaks, Vicki
Kerber, Anne
Kersten, Marie Jose
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S101 - S101
[20] Comparative Effectiveness of Lisocabtagene Maraleucel (Liso-cel) in PILOT in Patients (Pt) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) for Whom Transplant Was Not Intended (TNI) Versus Conventional Second-Line (2L) Chemotherapy Regimens in the Real World
Ghosh, Nilanjan
Sehgal, Alison R.
Liu, Fei Fei
Kostic, Ana
Crotta, Alessandro
Peng, Lily
De Benedetti, Marc
Gordon, Leo, I
BLOOD, 2022, 140 : 10430 - 10431

← 1 2 3 4 5 →